



SEQUENCE LISTING

<110> *Van Damme, Els A.J.M.*  
Hunt, Donald F.  
Engelhard, Victor H.

<120> HA-1 epitopes and uses thereof

<130> 2183-6047US

<140> 10/623,176  
<141> 2003-07-18

<150> 09/489,760  
<151> 2000-01-21

<150> EP 97202303.0  
<151> 1997-07-23

<150> PCT/NL98/00424  
<151> 1998-07-23

<150> JP 2000-504165  
<151> 2000-01-24

<160> 101

<170> PatentIn Ver. 2.1

<210> 1  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>

<221> SITE

<222> (1)..(9)

<400> 1

Val Leu Xaa Asp Asp Leu Leu Glu Ala  
1 5

<210> 2  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 2

Val Leu His Asp Asp Leu Leu Glu Ala  
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>

<221> SITE

<222> (1)..(9)

<400> 3

Lys Glu Cys Val Leu Xaa Asp Asp Leu  
1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 4

Lys Glu Cys Val Leu His Asp Asp Leu  
1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 5

Lys Glu Cys Val Leu Arg Asp Asp Leu

<210> 6  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(10)

<400> 6  
Lys Glu Cys Val Leu His Asp Asp Leu Leu  
1 5 10

<210> 7  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(10)

<400> 7  
Lys Glu Cys Val Leu Arg Asp Asp Leu Leu  
1 5 10

<210> 8  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>  
<221> SITE  
<222> (1)..(10)

<400> 8  
Lys Glu Cys Val Leu Xaa Asp Asp Leu Leu  
1 5 10

<210> 9  
<211> 10

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: peptide  
capable of binding HLA-A2.1

<220>  
<221> SITE  
<222> (1)..(10)

<400> 9  
Phe Leu Pro Ser Asp Cys Phe Pro Ser Val  
1 5 10

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 10  
Val Leu Arg Asp Asp Leu Leu Glu Ala  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HLA-A3 binder  
positive control peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 11  
Lys Gln Ser Ser Lys Ala Leu Gln Arg  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HLA-B60 binder  
positive control peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 12

Lys Glu Ser Thr Leu His Leu Val Leu  
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence  
revealed from peptide candidate m/z 550 wherein X  
can be I or L

<220>

<221> SITE

<222> (1)..(9)

<400> 13

Tyr Xaa Thr Asp Arg Val Met Thr Val  
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence of  
peptide candidate m/z 513 wherein X can be L or I

<220>

<221> SITE

<222> (1)..(9)

<400> 14

Val Xaa His Asp Asp Xaa Xaa Glu Ala  
1 5

<210> 15

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

```

<220>
<221> SITE
<222> (1)..(8)

<400> 15
Val Leu His Asp Leu Leu Glu Ala
1 5

<210> 16
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: reverse primer

<220>
<221> misc_feature
<222> (1)..(25)

<400> 16
gctcctgcat gacgctctgt ctgca 25

<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HA-1 (I)
      forward primer

<220>
<221> misc_feature
<222> (1)..(24)

<400> 17
gacgtcgtcg aggacatctc ccat 24

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: reverse primer

<220>
<221> misc_feature
<222> (1)..(25)

<400> 18
gaaggccaca gcaatcgtct ccagg 25

```

```

<210> 19
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer H1

<220>

<221> misc_feature
<222> (1)..(30)

<400> 19
ccttgagaaa ctttaaggagt gtgtgctgca 30

<210> 20
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer R1

<220>
<221> misc_feature
<222> (1)..(30)

<400> 20
ccttgagaaa ctttaaggagt gtgtgttgcg 30

<210> 21
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: forward primer

<220>
<221> misc_feature
<222> (1)..(33)

<400> 21
ccggcatgga cgtcgctcgag gacatctccc atc 33

<210> 22
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

```

<223> Description of Artificial Sequence: reverse primer

<220>

<221> misc\_feature  
<222> (1)..(30)

<400> 22

ctacttcagg ccacagcaat cgtctccagg

30

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE  
<222> (1)..(9)

<400> 23

Glu Cys Val Leu Arg Asp Asp Leu Leu  
1 5

<210> 24

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be H or R

<220>

<221> SITE

<222> (1)..(10)

<400> 24

Val Leu Xaa Asp Asp Leu Leu Glu Ala Arg  
1 5 10

<210> 25

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CFL5c8 primer  
wherein n is unknown

<220>

<221> misc\_feature

<222> (1)..(32)	
<400> 25	
cccccccccc ccccggtcta gannnnnnnn nn	32
<210> 26	
<211> 39	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: CFL5cT primer	
wherein n is unknown	
<220>	
<221> misc_feature	
<222> (1)..(39)	
<400> 26	
cccccccccc ccccggtcta gatttttttt tttttttvn	39
<210> 27	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: CP2 primer	
<220>	
<221> misc_feature	
<222> (1)..(27)	
<400> 27	
tcagaattca tgccccccccc cccccc	27
<210> 28	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: HA-1 (I)	
reverse primer	
<220>	
<221> misc_feature	
<222> (1)..(24)	
<400> 28	
gaaggccaca gcaatcggtct ccag	24
<210> 29	

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 (II)  
forward primer

<220>  
<221> misc\_feature  
<222> (1)..(21)

<400> 29  
acactgctgt cgtgtgaagt c 21

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 (II)  
reverse primer

<220>  
<221> misc\_feature  
<222> (1)..(20)

<400> 30  
tcaggccctg ctgtactgca 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: CD45 forward  
primer

<220>  
<221> misc\_feature  
<222> (1)..(20)

<400> 31  
ctgaaggaga ccattggta 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: CD45 reverse

primer

<220>  
<221> misc\_feature  
<222> (1)..(20)

<400> 32  
ggtactggta cacagttcga

20

<210> 33  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1  
polymorphic region wherein X can be H or R

<220>  
<221> SITE  
<222> (1)..(17)

<400> 33  
Glu Lys Leu Lys Glu Cys Val Leu Xaa Asp Asp Leu Leu Glu Ala Arg  
1 5 10 15

Arg

<210> 34  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 34  
Glu Lys Leu Lys Glu Cys Val Leu His  
1 5

<210> 35  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 35  
Glu Lys Leu Lys Glu Cys Val Leu Arg  
1 5

<210> 36  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 36  
Lys Leu Lys Glu Cys Val Leu His Asp  
1 5

<210> 37  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 37  
Lys Leu Lys Glu Cys Val Leu Arg Asp  
1 5

<210> 38  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 38  
Leu Lys Glu Cys Val Leu His Asp Asp

1

5

<210> 39  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)  
  
<400> 39  
Leu Lys Glu Cys Val Leu Arg Asp Asp  
1 5

<210> 40  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)  
  
<400> 40  
Glu Cys Val Leu His Asp Asp Leu Leu  
1 5

<210> 41  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)  
  
<400> 41  
Cys Val Leu His Asp Asp Leu Leu Glu  
1 5

<210> 42  
<211> 9  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 42

Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5

<210> 43

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 43

Val Leu His Asp Asp Leu Leu Glu Ala Arg  
1 5 10

<210> 44

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 44

Val Leu Arg Asp Asp Leu Leu Glu Ala Arg  
1 5 10

<210> 45

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE  
<222> (1)..(9)

<400> 45  
Leu His Asp Asp Leu Leu Glu Ala Arg  
1 5

<210> 46  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 46  
Leu Arg Asp Asp Leu Leu Glu Ala Arg  
1 5

<210> 47  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 47  
His Asp Asp Leu Leu Glu Ala Arg Arg  
1 5

<210> 48  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(9)

<400> 48  
Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5

<210> 49  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: 29 amino acid long HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(29)

<400> 49  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 50  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(14)

<400> 50  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu  
1 5 10

<210> 51  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(27)

<400> 51  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 52  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(19)

<400> 52  
His Asp Asp Leu Leu Glu Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
1 5 10 15

Gly Glu Ala

<210> 53  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(22)

<400> 53  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 54  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(13)

<400> 54

Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu  
1 5 10

<210> 55

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(25)

<400> 55

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 56

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(12)

<400> 56

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp  
1 5 10

<210> 57

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(17)

<400> 57

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala

<210> 58  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(10)

<400> 58  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu  
1 5 10

<210> 59  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: 29 amino acid  
long HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(29)

<400> 59  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 60  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(27)

<400> 60  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 61  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(28)

<400> 61  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu  
20 25

<210> 62  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(14)

<400> 62  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu  
1 5 10

<210> 63  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(22)

<400> 63  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15  
Ala Arg Arg Pro Arg Ala  
20

<210> 64  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide  
  
<220>  
<221> SITE  
<222> (1)..(13)

<400> 64  
Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu  
1 5 10

<210> 65  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide  
  
<220>  
<221> SITE  
<222> (1)..(12)

<400> 65  
Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 66  
<211> 26  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: HA-1 peptide  
  
<220>  
<221> SITE  
<222> (1)..(26)

<400> 66  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu

1

5

10

15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
20 25

<210> 67  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(25)

<400> 67

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 68  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(12)

<400> 68

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp  
1 5 10

<210> 69  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(17)

<400> 69

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala

<210> 70  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(19)

<400> 70  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg

<210> 71  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(21)

<400> 71  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg  
20

<210> 72  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE  
<222> (1)..(23)

<400> 72  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15  
Ala Arg Arg Pro Arg Ala His  
20

<210> 73  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: KIAA0223  
sequence derived from a presumed HA-1 negative  
individual

<220>  
<221> misc\_feature  
<222> (1)..(38)

<400> 73  
gagtgtgt tgctgtacga cctccttgag gcccgccg 38

<210> 74  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: KIAA0223  
sequence derived from a presumed HA-1 negative  
individual

<220>  
<221> SITE  
<222> (1)..(13)

<400> 74  
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 75  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: KIAA0223  
sequence derived from a presumed HA-1 homozygous  
positive individual

```

<220>
<221> misc_feature
<222> (1)..(38)

<400> 75
gagtgtgtgc tgcatgacga ctccttgag gcccggcg 38

<210> 76
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: KIAA0223
      sequence derived from a presumed HA-1 homozygous
      positive individual

<220>
<221> SITE
<222> (1)..(13)

<400> 76
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg
  1           5           10

<210> 77
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HA-1 peptide

<220>
<221> SITE
<222> (1)..(9)

<400> 77
Tyr Ile Gly Glu Val Leu Val Ser Val
  1           5

<210> 78
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: a 29 amino acid long HA-1A peptide

<400> 78

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu
  1           5           10           15

```

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 79  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 79

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu  
1 5 10

<210> 80  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 80

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 81  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 81

His Asp Asp Leu Leu Glu Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
1 5 10 15

Gly Glu Ala

<210> 82  
<211> 22  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide  
  
<400> 82

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 83  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide  
  
<400> 83

Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu  
1 5 10

<210> 84  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide  
  
<400> 84

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 85  
<211> 12  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 85

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp  
1 5 10

<210> 86

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 86

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala

<210> 87

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 87

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu  
1 5 10

<210> 88

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: a 29 amino acid long HA-1R peptide

<400> 88

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 89  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 89

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 90  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 90

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu  
20 25

<210> 91  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 91

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu  
1 5 10

<210> 92  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 92

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 93  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 93

Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu  
1 5 10

<210> 94  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 94

Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 95  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 95

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
20 25

<210> 96

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 96

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 97

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 97

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp  
1 5 10

<210> 98

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 98

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala

<210> 99  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 99

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg

<210> 100  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 100

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg  
20

<210> 101  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29  
amino acid long HA-1R peptide

<400> 101

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His  
20